Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system.
Drug Dev Ind Pharm
; 47(1): 83-91, 2021 Jan.
Article
en En
| MEDLINE
| ID: mdl-33289591
ABSTRACT
OBJECTIVE:
This study developed a novel child-friendly drug delivery system for pediatric HIV treatment a liquid, taste-masked, and solvent-free monoolein-based nanoparticles formulation containing indinavir (0.1%).SIGNIFICANCE:
Adherence to antiretroviral therapy by pediatric patients is difficult because of the lack of dosage forms adequate for children.METHODS:
Monoolein-based nanoparticles were developed. The particle size, zeta potential, pH, drug content, small angle X-ray scattering, stability, in vitro drug release profile, biocompatibility, toxicity, and taste-masking properties were evaluated.RESULTS:
Monoolein-based formulations containing indinavir had nanosized particles with 155 ± 7 nm, unimodal particle size distribution, and polydispersity index of 0.16 ± 0.03. The zeta potential was negative (-31.3 ± 0.3 mV) and pH was neutral (7.78 ± 0.01). A 96% drug incorporation efficiency was achieved, and the indinavir concentration remained constant for 30 days. Polarized light microscopy revealed isotropic characteristics. Transmission electron microscopy images showed spherical shaped morphology. Small-angle X-ray scattering displayed a form factor broad peak. Indinavir had a sustained release from the nanoparticles. The system was nonirritant and was able to mask drug bitter taste.CONCLUSIONS:
Monoolein-based nanoparticles represent a suitable therapeutic strategy for antiretroviral treatment with the potential to reduce the frequency of drug administration and promote pediatric adherence.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Indinavir
/
Nanopartículas
/
Glicéridos
Límite:
Child
/
Humans
Idioma:
En
Revista:
Drug Dev Ind Pharm
Año:
2021
Tipo del documento:
Article
País de afiliación:
Brasil